Benzodiazepine Information Coalition
Educating about the potential adverse effects of
benzodiazepines taken as prescribed.
Benzo Bulletin: Loneliness, Aging, and Polypharmacy — Doctors advised to try “social prescribing” in place of more meds
As an integral part of our outreach efforts, we offer awareness and education via many well-known media outlets and publications.
We offer awareness and education through public speaking about benzodiazepine issues both in public and professional settings.
Research and Publications
Through our research we contribute to the scientific discussion about benzodiazepines.
Conferences and Events
Our participation in conferences and other events brings the benzodiazepine-harm message to the public.
Educating about the potential adverse effects of benzodiazepines taken as prescribed.
Who We Are
We are a group of patients and medical professionals who believe the over-prescription of benzodiazepines without proper warning has resulted in a growing national epidemic of benzodiazepine injury.
We seek to break the stigma and raise awareness around prescribed benzodiazepine injury, provide a voice to the patients who are suffering, and facilitate research and access to competent, evidence-based medical care for those impacted by benzodiazepine induced disability.
Why We Are Different
With both professional and patient experience, we exist solely to raise awareness of the complex issues surrounding prescribed benzodiazepine use, and to prevent further patient injury.
In the summer of 2016, Benzodiazepine Information Coalition formed as a U.S. non-profit organization dedicated to advocating for awareness and reform around the dangers of benzodiazepines, motivated by the years of watching benzodiazepine-injury support groups grow in membership by the thousands without any corresponding increase in attention from the public or medical community.
We seek change by educating and partnering with doctors, mental health providers, journalists, lawmakers, researchers, the benzodiazepine-impacted community, and society at large.
Our work will continue until benzodiazepines are at the forefront of the national healthcare conversation; until patients are given adequate informed consent; until the rate of injury is significantly lowered; and until those cases that remain are understood and treated appropriately.